Overview

A Phase Ib/Ⅱ Study of NTQ1062 in Combination With Fulvestrant in Patients With Advanced HR Positive /HER-2 Negative Breast Cancer

Status:
Recruiting

Trial end date:
2025-07-01

Target enrollment:

Participant gender:

Summary

This is an open-label, single-arm phase 1b study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor efficacy of NTQ1062 in combination with Fulvestrant in patients with locally advanced or metastatic HR positive/HER-2 negative breast cancer.

Phase:

Phase 1

Details

Lead Sponsor:

Nanjing Chia-tai Tianqing Pharmaceutical

Treatments:

Fulvestrant